Source comparison
Tesamorelin vs. Other GHRH Analogs: A Timeline Comparison
It’s helpful to understand how tesamorelin fits into the broader landscape of growth hormone secretagogues. It's not the only tool, and knowing the differences is key to designing effective research. Each has a unique structure and pharmacokinetic profile, whi
This comparison does not assign a generated winner or score.
- It’s helpful to understand how tesamorelin fits into the broader landscape of growth hormone secretagogues. It's not the only tool, and knowing the differences is key to designing effective research. Each has a unique structure and pharmacokinetic profile, which directly impacts its timeline of action.
- Tesamorelin
- ~25-35 minutes
- Visceral Adipose Tissue (VAT) reduction, metabolic health
- 12-26 weeks for significant VAT changes
- Sermorelin
- ~10-12 minutes
- General anti-aging, GH optimization, broader effects
- 3-6 months for general wellness improvements
- CJC-1295 (No DAC)
- ~30 minutes
- Sustained GH release, often stacked with GHRPs
- 8-12 weeks for initial composition changes
- As you can see, while they all work on the same fundamental pathway, their design lends them to different applications and timelines. Sermorelin, with its shorter half-life, provides a very natural, short pulse, often researched for general wellness over longer periods. CJC 1295 NO DAC (also known as Mod GRF 1-29) provides a similarly strong pulse. Tesamorelin, however, was specifically engineered and studied for its robust and targeted effect on visceral fat, with the 26-week mark being the most critical data point.